Growth and scale Eurofins DiscoverX operates within a growing biotech landscape with revenue in the 50–100 million range and a global network of R&D centers, suggesting opportunities to upsell expanded assay portfolios, cell line development, and QC services to mid-size biotechs and CROs looking to scale programs.

Bioassay and engagement The company specializes in cell-based assays, target engagement, and bioassays for immuno-oncology and related targets, presenting cross-sell potential to labs seeking standardized CRO-like certification programs, ready-to-use kits, and validated reagents for faster project timelines.

Strategic partnerships Past collaborations with Catalent and a CRO certification initiative indicate openness to channel partnerships and co-development opportunities, suggesting potential to expand through distributors, CDMOs, and pharma services networks.

Global capability Three centers of excellence in the US and France, plus a broad product suite, point to geographic and product breadth advantages for multinational customers needing consistent support across discovery, preclinical, and QC stages.

Product-led value A strong portfolio of assays, stable cell lines, and ready-to-use kits enables compelling value propositions for pharma and biotech customers seeking reliable, reproducible results, bolstering opportunities for renewals, expanded licenses, and higher-margin kit sales.